1 Guidance

1.1 Current evidence on the safety and efficacy of catheterless oesophageal pH monitoring appears adequate to support the use of this technique provided that normal arrangements are in place for consent, audit and clinical governance.

2 The procedure

2.1 Indications

2.1.1 Gastro-oesophageal reflux disease (GORD) is a common disorder in which a backwash of gastric juices into the oesophagus leads to inflammation and pain. Symptoms include heartburn, belching and regurgitation of gastric contents. Complications of GORD include oesophageal stricture and Barrett’s oesophagus (which is associated
with carcinoma of the oesophagus). The frequency of exposure to 
gastric acid over a given period provides a measure of the severity of the 
disease and can be measured by oesophageal pH monitoring. Common 
indications for pH monitoring include symptoms that are refractory to 
therapy with proton pump inhibitors, evaluation before surgery and 
recurrence of symptoms after anti-reflux surgery.

2.1.2 Ambulatory oesophageal pH monitoring is commonly undertaken by 
transnasal placement of a pH probe on a catheter. However, this can 
cause nasal and pharyngeal discomfort, which may cause the patient to 
alter their diet and activity, potentially giving misleading results. 
Catheterless oesophageal pH monitoring is suitable for patients who do 
not tolerate nasal intubation.

2.2 Outline of the procedure

2.2.1 A catheterless pH monitoring system comprises a plastic capsule that 
houses a pH sensor and a transmitter. After endoscopy, the capsule is 
inserted into the oesophagus and is attached at a chosen site on the 
esophageal wall by a vacuum that draws the oesophageal mucosa into 
a well on the side of the capsule. A spring-loaded pin is then released 
across the well, tangential to the axis of the oesophagus, to fix the 
capsule in place. Correct placement and attachment of the capsule is 
confirmed endoscopically. The capsule continuously monitors 
esophageal pH and transmits the data every few seconds to a small 
receiver worn by the patient. After a few days, the capsule detaches 
from the oesophageal wall and passes through the digestive tract.

2.3 Efficacy

2.3.1 During a randomised controlled study (n = 50), the frequency of GORD 
symptoms was similar during catheterless and catheter-based 
monitoring. Overall quality-of-life scores based on the short-form SF-36 
scale were also similar between the groups. Significantly more patients 
who underwent the catheterless monitoring (88%) than the catheter-
based monitoring (48%) were willing to have a repeat test if necessary (p 
= 0.005).
2.3.2 In a within-patient study of 33 patients who had both catheterless and catheter-based monitoring simultaneously, a total of 1388 reflux episodes were recorded over a 24-hour period. Of these reflux episodes, 41% (563/1388) were recorded by both devices, 52% (724/1388) were recorded only by the catheter-based system and 7% (101/1388) only by the catheterless monitor. Overall the concordance of reflux episodes was 88% (Kappa statistic 0.76).

2.3.3 A non-randomised controlled study in healthy volunteers found that, after calibration, the catheterless monitor identified significantly fewer reflux episodes (mean 37.9) during 24-hour monitoring than a catheter-based system (mean 69.8) (p < 0.05). Whether these findings relate to asymptomatic reflux in healthy volunteers or previously undetected disease is unclear. For more details, refer to the 'Sources of evidence' section.

2.3.4 The Specialist Advisers noted that catheterless oesophageal pH monitoring may provide accurate recording under conditions of normal daily activity.

2.4 Safety

2.4.1 Follow-up across all the studies included in the overview is based solely on the period of monitoring used; no longer-term data are available.

2.4.2 Among patients in a case series and in the catheterless monitoring arms of controlled studies, the incidences of chest pain reported were 5% (4/85), 33% (26/80) and 36% (9/25). In one of these studies, 2% (2/85) of patients requested immediate removal of the capsule after the 48-hour monitoring period because of chest pain.

2.4.3 In a randomised controlled trial, the incidence of chest pain was higher with a catheterless monitor (60%) compared with a catheter-based system (24%) (p = 0.01). However, fewer patients reported difficulty swallowing (36%) with the catheterless system than with the catheter-based approach (68%) (p = 0.024). In the same study, significantly fewer patients with the catheterless monitoring had nose pain, runny nose, throat pain, throat discomfort or headache. Also, among patients in
employment, 58% of the patients with a catheterless capsule were able to return to work during monitoring, compared with 11% of those with the catheter-based system (p = 0.049).

2.4.4 In a study of 44 children aged 6–19 years who had catheterless oesophageal pH monitoring, 95% (36/38) of parents were willing to allow their child to undergo further catheterless monitoring. In this study, the 12 patients who had previously had nasal catheter monitoring were reported to prefer the catheterless method.

2.4.5 There were no reports in the reviewed literature of adverse events relating to the endoscopic component of the procedure. For more details, refer to the ‘Sources of evidence’ section.

2.4.6 The Specialist Advisers reported that adverse events included chest discomfort, mucosal tear, failure of the capsule to detach and failure of data retrieval. They also noted that additional theoretical complications included haemorrhage, oesophageal perforation, oesophageal ulceration, capsule misplacement and failure to pass the capsule once detached.

2.5 Other comments

2.5.1 It was noted that this procedure would be particularly appropriate in children and other patients who may not tolerate the nasal intubation required for catheter-based monitoring.

2.5.2 It was also noted that this procedure may be unsuitable for some patients, for example patients with pacemakers.

3 Further information

3.1 The Institute has issued a clinical guideline on managing dyspepsia in adults in primary care.

Andrew Dillon
Chief Executive
July 2006
Sources of evidence

The evidence considered by the Interventional Procedures Advisory Committee is described in the following document.


Information for patients

NICE has produced information on this procedure for patients and carers. It explains the nature of the procedure and the guidance issued by NICE, and has been written with patient consent in mind.

4 About this guidance

NICE interventional procedure guidance makes recommendations on the safety and efficacy of the procedure. It does not cover whether or not the NHS should fund a procedure. Funding decisions are taken by local NHS bodies after considering the clinical effectiveness of the procedure and whether it represents value for money for the NHS. It is for healthcare professionals and people using the NHS in England, Wales, Scotland and Northern Ireland, and is endorsed by Healthcare Improvement Scotland for implementation by NHSScotland.

This guidance was developed using the NICE interventional procedure guidance process.

We have produced a summary of this guidance for patients and carers. Information about the evidence it is based on is also available.

Changes since publication

19 January 2012: minor maintenance.

Your responsibility

This guidance represents the views of NICE and was arrived at after careful consideration of the available evidence. Healthcare professionals are expected to take it fully into
account when exercising their clinical judgement. This guidance does not, however, override the individual responsibility of healthcare professionals to make appropriate decisions in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

Implementation of this guidance is the responsibility of local commissioners and/or providers. Commissioners and providers are reminded that it is their responsibility to implement the guidance, in their local context, in light of their duties to avoid unlawful discrimination and to have regard to promoting equality of opportunity. Nothing in this guidance should be interpreted in a way which would be inconsistent with compliance with those duties.

Copyright

© National Institute for Health and Clinical Excellence 2006. All rights reserved. NICE copyright material can be downloaded for private research and study, and may be reproduced for educational and not-for-profit purposes. No reproduction by or for commercial organisations, or for commercial purposes, is allowed without the written permission of NICE.

Contact NICE

National Institute for Health and Clinical Excellence
Level 1A, City Tower, Piccadilly Plaza, Manchester M1 4BT

www.nice.org.uk
nice@nice.org.uk
0845 033 7780

Endorsing organisation

This guidance has been endorsed by Healthcare Improvement Scotland.